|
|
||||||||
From the Henry Ford Hospital, Department of Neurology (Dr. Welch), Detroit. MI: Syntex Research (Dr. Ellis), Palo Alto, CA; and Baylor College of Medicine, Department of Neurology (Dr. Keenan), Houston, TX.
Naproxen sodium, a potent inhibitor of prostaglandin biosynthesis and platelet aggregation, was studied for efficacy in migraine prophylaxis in a randomized, double-blind, placebo-controlled, crossover trial. On naproxen treatment, 52% of the patients had no severe headaches, whereas 19 % had no severe headaches during placebo. Naproxen sodium was much better than placebo when patients' diaries were reviewed for severity of attacks, nausea, vomiting, activity reduction, duration of headache, and decreased use of therapeutic medication. The degree of platelet inhibition did not correlate with efficacy in preventing headache. Naproxen sodium can be recommended as a drug of first choice for migraine prevention.
Address correspondence and reprint requests to Dr. Welch, Henry Ford Hospital. Department of Neurology, 2799 West Grand Boulevard, Detroit, M1 48202.
Presented in part at the thirty-sixth annual meeting of the American Academy of Neurology, Boston, MA, April 1984.
Accepted for publication December 21, 1984.
This article has been cited by other articles:
![]() |
V. Snow, K. Weiss, E. M. Wall, C. Mottur-Pilson, and for the American Academy of Family Physicians and Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache Ann Intern Med, November 19, 2002; 137(10): 840 - 849. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.M.A. Welch Drug Therapy of Migraine N. Engl. J. Med., November 11, 1993; 329(20): 1476 - 1483. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |